FilingReader Intelligence
Hengrui Pharma posts 30% profit jump, launches buyback
August 20, 2025 at 05:07 PM UTC•By FilingReader AI
Jiangsu Hengrui Medicine reported interim revenue up 15.9% to RMB15,761.2 million and net profit surging 29.7% to RMB4,450.1 million, driven by innovative drug sales and licensing revenues.
The company will repurchase RMB1-2 billion of A-shares for a new employee stock ownership plan covering up to 1,316 participants.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
H-share announcement - interim results announcement for the six months ended 30 June 2025August 20, 2025 at 08:00 AM UTC
Hengrui Therapeutics 2025 A-share employee stock ownership plan (draft)August 20, 2025 at 08:00 AM UTC
Summary of Hengrui Pharmaceuticals' 2025 A-share employee stock ownership plan (draft)August 20, 2025 at 08:00 AM UTC
Jiangsu Hengrui Medicine co., Ltd. announcement on the plan to repurchase the company's A-share shares through centralized bidding transactionsAugust 20, 2025 at 08:00 AM UTC
Hengrui Therapeutics 2025 semiannual reportAugust 20, 2025 at 08:00 AM UTC
Hengrui Therapeutics 2025 semi-annual report summaryAugust 20, 2025 at 08:00 AM UTC
Jiangsu Hengrui Medicine co., ltd. announcement on wealth management with idle self-owned fundsAugust 20, 2025 at 08:00 AM UTC
Announcement of resolutions of the eighteenth meeting of the ninth board of directors of Hengrui MedicineAugust 20, 2025 at 08:00 AM UTC
Announcement by Hengrui Medicine on the appointment of overseas audit firm for 2025August 20, 2025 at 08:00 AM UTC
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime